Laying the foundation for even greater hope.
As part of our strategic goal of achieving future designation as an NCI Comprehensive Cancer Center, MCI has created an Executive Advisory Board, which serves to provide advice to the Director, USA Mitchell Cancer Institute (MCI), and President, University of South Alabama, on all matters pertinent to the oncology healthcare and research missions of the MCI, particularly in regard to achieving NCI designation.
An external expert Advisory Board is a requirement for any prospective or extant NCI Comprehensive Cancer Center. Prospective NCI Centers are substantially judged by the quality of the external advisors that they attract and engage. Creation of this board will immediately and substantially enhance:
• The scientific and clinical credibility of the MCI
• Financial viability of the MCI clinical services business
• Competitiveness for federal and other national grant funding of cancer-related research
• Competitiveness, national/international networking for and access to philanthropic support of MCI programs
• Competitiveness, national/international networking for and access to top-tier funding opportunities from pharmaceutical and biotechnology industries
• Competitiveness, national/international networking for continued recruitment of highest quality oncology physicians and cancer researchers to the MCI faculty
• Partnerships with affiliate institutions throughout region that are mutually beneficial and enhance oncology care and research
Bruce Chabner, M.D., Board Chair
Alex Adjei, M.D., Ph.D.
Michael Grever, M.D.
Jay Loeffler, M.D.
Joyce O’ Shaughnessy, M.D.
Edward Partridge, M.D.
||Bruce Chabner, M.D., MCI Executive Advisory Board Chair
Professor of Medicine at Harvard Medical School
Director of Clinical Research at Massachusetts General Hospital Cancer Center
MCI’s Executive Advisory Board is chaired by Dr. Bruce Chabner, Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center
Dr. Chabner received his M.D. from Harvard cum laude in l965 and joined the National Cancer Institute (NCI) as a Senior Investigator in the Laboratory of Chemical Pharmacology in l971, he participated in the training of clinical and research fellows as Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program and its fellowship programs in medical, pediatric, radiation, and surgical oncology, and Director of the Division of Cancer Treatment, NCI. During this time, he maintained an active laboratory program in cancer pharmacology, focusing on the mechanism of action, and resistance of antifolates and other antimetabolites, and led the development of Taxol.
In l995, Dr. Chabner joined the Massachusetts General Hospital as Clinical Director of its cancer center and Chief of Hematology/Oncology. With the formation of the Dana-Farber/Harvard Cancer Center, he assumed responsibilities as Associate Director for Clinical Sciences of that consortium, which includes the Massachusetts General Hospital, Brigham & Women’s Hospital, Dana-Farber Cancer Institute and Beath Israel Deaconess Medical Center
Dr. Chabner has received numerous awards for his work, including Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of the Cancer Patient. He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its fourth edition, has contributed the chapter on Antineoplastics in Goodman and Gilman’s Textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.
Dr. Chabner is a senior editor for the Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute.
||Alex Adjei, M.D., Ph.D.
Senior Vice President of Clinical Research
Professor and Chair, Department of Medicine
The Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute
Dr. Alex Adjei received his M.D. from the University of Ghana Medical School in Legon, Ghana, and also holds a Ph.D. from the University of Alberta, in Edmonton, Alberta, Canada. Currently he is Senior Vice President of Clinical Research and Professor and Chair, Department of Medicine at Roswell Park Cancer Institute and School of Medicine and Biomedical Sciences at State University of New York at Buffalo. A leading expert in the field of lung cancer, Dr. Adjei’s areas of research interest include the development of novel agents for the therapy of solid tumors. He is a Board Certified Diplomate in Internal Medicine and Medical Oncology from the American Board of Internal Medicine.
||Michael Grever, M.D.
Chair / Professor, Department of Internal Medicine, Ohio State University College of Medicine James Cancer Hospital and Solove Research Institute (The James)
Dr. Michael Grever received his M.D. from the University of Pittsburgh and followed that with a residency at Presby University Hospital and a fellowship at Ohio State University. He is currently Professor and Chair of the Department of Internal Medicine, Ohio State University College of Medicine James Cancer Hospital and Solove Research Institute (The James). Among Dr. Grever’s areas of expertise are Hematology, Medical Oncology and Internal Medicine, and his special research interests include anti-cancer drug development; cancer genetics and experimental therapeutics. Dr. Grever is Board Certified in Hematology, Oncology and Internal Medicine.
||Jay Loeffler, M.D.
Herman and Joan Suit Professor of Radiation Oncology, Department of Radiation Oncology, Harvard Medical School
Chair, Radiation Oncology, Massachusetts General Hospital, Dana-Farber / Harvard Cancer Center
A leading expert on Radiosurgery and Radiation Injuries, Dr. Jay Loeffler received his M.D. from the Warren Alpert Medical School Of Brown University, and followed that with a residency at Harvard Joint Center and a fellowship at Harvard School of Public Health. With a special research interest in proton therapy, Dr. Loeffler currently serves as a Professor of Radiation Oncology at Harvard Medical School, and is the Chair of Radiation Oncology at Massachusetts General Hospital, Dana-Farber / Harvard Cancer Center.
||Joyce O’ Shaughnessy, M.D.
Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center
A leading expert on Adjuvant Chemotherapy, Dr. Joyce O’ Shaughnessy received her M.D. from Yale University School of Medicine, and followed that with a residency at s Massachusetts General Hospital and a fellowship at the National Cancer Institute. Currently, Dr. O’ Shaughnessy is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center. With a special research interest in Breast Cancer, she is Board Certified in Internal Medicine and Oncology.
||Edward Partridge M.D.
Co-Director, Co-Principal Investigator and Research Program Leader, Minority Health & Health Disparities Research Center Director, Professor of Gynecologic Oncology and Professor of Surgery, UAB Comprehensive Cancer Center
Dr. Edward Partridge is a leading expert in Gynecologic Oncology, and currently is Co-Director, Co-Principal Investigator and Research Program Leader at Minority Health & Health Disparities Research Center, as well as Director, Professor of Gynecologic Oncology and Professor of Surgery at UAB Comprehensive Cancer Center. Dr. Patridge received his M.D. from the University of Alabama School of Medicine, and has Board Certifications in Gynecologic Oncology and Obstetrics & Gynecology. Among his many areas of research interest are Cancer Control and Prevention, Cervical cancer, community based research, gynecology oncology, minority health disparities, and ovarian cancer.